Editorial board member Ulka Vaishampayan from the Karmanos Cancer Center, Wayne State University, Detroit, MI, US, talks to us about the place of personalized therapy in patients with advance renal cancer and the potential role of X4P-001 in treatment paradigms in the near future.
1. What are the main unmet needs in the treatment of advanced renal cancer? (0:11)
2. What factors do you take into account when selecting a therapy for an individual patient with advanced renal cancer? (0:43)
3. What are the most useful molecular markers to inform selection of therapy? (1:57)
4. What is the mechanism of action of X4P-001? (3:34)
5. Could you tell us a little about your recent phase I/II study evaluating the efficacy and safety of X4P-001 in combination with axitinib? (3:56)
Speaker disclosures: Ulka Vaishampayan has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
